[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Mangili G, De Marzi P, Beatrice S, Rabaiotti E, Viganò R, Frigerio L, Gentile C, Fazio F: Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings. BMC Cancer; 2006;6:198
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings.
  • BACKGROUND: There is still much debate about the best adjuvant therapy after surgery for endometrial cancer (EC) and there are no current guidelines.
  • METHODS: Twenty-three patients with high-risk EC (stage IIB, IIIA, IIIC or IC G3 without lymphadenectomy or with aneuploid tumor) underwent primary surgery and were then referred for adjuvant therapy.
  • P was given at a dose of 60 mg/m2 once weekly for five weeks during RT, which consisted of a total radiation dose of 50.4 Gy.
  • Overall survival and disease-free survival were calculated from the time of surgery.
  • RESULTS: A total of 157 cycles of P were administered both during radiotherapy and consolidation chemotherapy.
  • Median time to recurrence was 18.6 months (range 3-28).
  • In this group median time to recurrence was 19.2 months (range 3-28).
  • CONCLUSION: This small series demonstrates pelvic radiotherapy in combination with weakly P followed by three consolidation chemotherapy cycles as an effective combined approach in high risk endometrial carcinoma patients.
  • [MeSH-major] Chemotherapy, Adjuvant / methods. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / radiotherapy. Paclitaxel / therapeutic use. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Aged. Disease-Free Survival. Female. Humans. Middle Aged. Pilot Projects. Ploidies. Radiation Dosage. Recurrence. Risk Factors. Treatment Failure

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Radiat Oncol. 2000 Jan;10(1):23-8 [10671655.001]
  • [Cites] Cell Motil Cytoskeleton. 2000 Mar;45(3):223-34 [10706777.001]
  • [Cites] Lancet. 2000 Apr 22;355(9213):1404-11 [10791524.001]
  • [Cites] Gynecol Obstet Invest. 2000;50(2):127-32 [10965198.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):53-7 [11277649.001]
  • [Cites] J Epidemiol Biostat. 2001;6(1):47-86 [11385776.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1145-53 [11483323.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4048-53 [11600606.001]
  • [Cites] J Reprod Med. 2002 Mar;47(3):173-89; discussion 189-90 [11933681.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(3):216-20 [12094958.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):537-46 [13678721.001]
  • [Cites] Cancer Invest. 2003;21(6):887-96 [14735693.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6D):5191-6 [14981988.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73 [15093913.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):345-52 [15099944.001]
  • [Cites] Histopathology. 2004 Jun;44(6):603-14 [15186276.001]
  • [Cites] Cancer Treat Rep. 1979 Jan;63(1):21-7 [369691.001]
  • [Cites] Obstet Gynecol. 1980 Oct;56(4):419-27 [6999399.001]
  • [Cites] Obstet Gynecol. 1982 Feb;59(2):225-8 [7043339.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):166-71 [2298404.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):305-8 [2227540.001]
  • [Cites] Gynecol Oncol. 1991 Jan;40(1):55-65 [1989916.001]
  • [Cites] Am J Obstet Gynecol. 1994 Jun;170(6):1677-81; discussion 1681-2 [8203425.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2682-6 [7989944.001]
  • [Cites] Gynecol Oncol. 1995 May;57(2):138-44 [7729725.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1996 Jan;48(1):45-51 [8576621.001]
  • [Cites] Anticancer Drugs. 1996 Feb;7(2):182-8 [8740723.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] Clin Obstet Gynecol. 1996 Sep;39(3):716-27 [8862895.001]
  • [Cites] Gynecol Oncol. 1996 Oct;63(1):34-9 [8898165.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):861-3 [8922203.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6 Suppl 16):108-12 [9007135.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):885-95 [9128966.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • [Cites] Am J Clin Oncol. 1996 Jun;19(3):290-1 [8638543.001]
  • (PMID = 16869961.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC1559635
  •  go-up   go-down


2. Alduaij A, Hansen K, Zhang C: Primary follicular lymphoma of the fallopian tube found incidentally in a patient treated for endometrial carcinoma: a case report. Diagn Pathol; 2010;5:44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary follicular lymphoma of the fallopian tube found incidentally in a patient treated for endometrial carcinoma: a case report.
  • We report a rare case of primary lymphoma of fallopian tube in a 68-year-old woman who underwent total hysterectomy and bilateral salpingo-oophorectomy for endometrial carcinoma.
  • The left fallopian tube revealed a 1 cm nodule that histologically showed diffuse lymphoid follicles consisting of small cleaved lymphocytes and occasional larger cells.
  • Polymerase chain reaction confirmed a monoclonal B-cell population.
  • She did not receive chemotherapy and remained disease free for 13 months after surgery.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / pathology. Hysterectomy. Incidental Findings. Lymphoma, Follicular / pathology. Neoplasms, Multiple Primary. Ovariectomy
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Intraoperative Period. Translocation, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2002 Sep;86(3):384-6 [12217767.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1933-43 [6627208.001]
  • [Cites] Int J Gynecol Pathol. 2006 Jan;25(1):1-21 [16306779.001]
  • [Cites] Int J Gynecol Pathol. 1991;10(4):394-401 [1774110.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):736-8 [15581994.001]
  • [Cites] Pathol Annu. 1991;26 Pt 1:227-63 [2014141.001]
  • (PMID = 20584306.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2905343
  •  go-up   go-down


3. Mundhenke C, Weigel MT, Sturner KH, Roesel F, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Hilpert F, Jonat W, Maass N: Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects. J Cancer Res Clin Oncol; 2008 Dec;134(12):1397-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.
  • PURPOSE: Imatinib is a small molecule inhibiting the tyrosine kinases bcr-abl, c-kit, PDGFR-alpha and PDGFR-beta.
  • Investigations were performed to screen ovarian cancer cell lines and tumor samples for target receptor expression.
  • Effects of Imatinib on cell proliferation and apoptosis induction were measured with and without additional cytotoxic agents.
  • METHODS: Expression patterns of abl, c-kit, PDGFR-alpha and PDGFR-beta (Imatinib targets) were studied in 5 cell lines and 111 tissue arrays by PCR and immunohistochemistry.
  • RESULTS: All cell lines expressed abl and PDGFR-beta.
  • C-kit was only expressed in 2/5 cell lines and PDGFR-alpha in 4/5.
  • Imatinib reduced cell growth and lead to pro-apoptotic changes.
  • CONCLUSIONS: Our results suggest that Imatinib may be useful for the specific treatment of ovarian cancer as an add-on to conventional chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Cell Proliferation / drug effects. Ovarian Neoplasms / drug therapy. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Receptor, Platelet-Derived Growth Factor beta / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Benzamides. Carboplatin / administration & dosage. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Female. Humans. Imatinib Mesylate. Immunoenzyme Techniques. Paclitaxel / administration & dosage. Piperazines / administration & dosage. Proto-Oncogene Proteins c-abl / genetics. Proto-Oncogene Proteins c-abl / metabolism. Proto-Oncogene Proteins c-kit / genetics. Proto-Oncogene Proteins c-kit / metabolism. Pyrimidines / administration & dosage. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Tissue Array Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33490-500 [12087097.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3312-22 [11454878.001]
  • [Cites] Biotechniques. 1995 Oct;19(4):640-9 [8777059.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4217-26 [15483033.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):78-86 [15047217.001]
  • [Cites] J Cell Physiol. 1998 Dec;177(3):426-38 [9808151.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S28-36 [12528770.001]
  • [Cites] Endocrinology. 2004 Apr;145(4):2014-22 [14701673.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23432-40 [12697749.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] Mol Cancer Ther. 2003 Aug;2(8):699-709 [12939459.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):126-31 [16271384.001]
  • [Cites] J Pathol. 2002 Apr;196(4):467-77 [11920744.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3319-26 [10955819.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):385-94 [15617027.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1246-50 [11350890.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10 (2):681-90 [14760091.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):897-908 [14871965.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6271-3; author reply 6273-4 [16135502.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):122-31 [17169414.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1A):407-16 [10769688.001]
  • [Cites] Blood. 2002 Aug 1;100(3):1014-8 [12130516.001]
  • [Cites] Blood. 2001 Apr 1;97(7):1999-2007 [11264164.001]
  • [Cites] Blood. 2001 Feb 15;97(4):1086-91 [11159541.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1087-92 [11861387.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jul-Aug;17(4):784-8 [17343607.001]
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):768-76 [10842189.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3084-92 [10963636.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2060-9 [16331269.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):2048-55 [15583695.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2929-34 [11306470.001]
  • (PMID = 18465140.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 8A1O1M485B / Imatinib Mesylate; BG3F62OND5 / Carboplatin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 2.7.10.2 / Proto-Oncogene Proteins c-abl; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


Advertisement
4. Mundt AJ, Murphy KT, Rotmensch J, Waggoner SE, Yamada SD, Connell PP: Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1154-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma.
  • OBJECTIVE: To determine the outcome, pattern(s) of failure, and optimal treatment volume in Stage IIIC endometrial carcinoma patients treated with surgery and postoperative radiation therapy (RT).
  • METHODS: Between 1983 and 1998, 30 Stage IIIC endometrial carcinoma patients were treated with primary surgery and postoperative RT at the University of Chicago.
  • Adjuvant vaginal brachytherapy (VB) was delivered in 10, chemotherapy in 5, and hormonal therapy in 7 patients.
  • No patient developed an isolated abdominal recurrence.
  • Two patients developed significant RT sequelae: chronic diarrhea in 1 patient treated with WPRT and VB, and small bowel obstruction in 1 patient treated with EFRT.
  • CONCLUSION: FIGO Stage IIIC disease comprises a small percentage of endometrial carcinoma patients but carries a poor prognosis.
  • Given the predominance of failure in distant sites, attention should be focused on the development of systemic chemotherapy protocols.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy. Hysterectomy. Ovariectomy. Radiotherapy, Adjuvant
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Antineoplastic Agents, Hormonal / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Chicago / epidemiology. Combined Modality Therapy. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / radiotherapy. Cystadenocarcinoma, Papillary / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Life Tables. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483324.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


5. Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, Zhang DD: High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res; 2010 Jul 1;70(13):5486-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High levels of Nrf2 determine chemoresistance in type II endometrial cancer.
  • Type II endometrial cancer, which mainly presents as serous and clear cell types, has proved to be the most malignant and recurrent carcinoma among various female genital malignancies.
  • Nrf2 is constitutively upregulated in several types of human cancer tissues and cancer cell lines.
  • Furthermore, inhibition of Nrf2 expression sensitizes cancer cells to chemotherapeutic drugs.
  • In this study, the constitutive level of Nrf2 was compared in different types of human endometrial tumors.
  • It was found that Nrf2 was highly expressed in endometrial serous carcinoma (ESC), whereas complex hyperplasia and endometrial endometrioid carcinoma (EEC) had no or marginal expression of Nrf2.
  • Likewise, the ESC-derived SPEC-2 cell line had a higher level of Nrf2 expression and was more resistant to the toxic effects of cisplatin and paclitaxel than the Ishikawa cell line, which was generated from EEC.
  • Silencing of Nrf2 rendered SPEC-2 cells more susceptible to chemotherapeutic drugs, whereas it had a limited effect on Ishikawa cells.
  • Inhibition of Nrf2 expression by overexpressing Keap1 sensitized SPEC-2 cells or SPEC-2-derived xenografts to chemotherapeutic treatments using both cell culture and severe combined immunodeficient mouse models.
  • Collectively, we provide a molecular basis for the use of Nrf2 inhibitors to increase the efficacy of chemotherapeutic drugs and to combat chemoresistance, the biggest obstacle in chemotherapy.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Trends Biochem Sci. 2009 Apr;34(4):176-88 [19321346.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Feb;26(2):175-82 [11804867.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):768-80 [14570043.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(16):7130-9 [15282312.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] In Vitro Cell Dev Biol. 1990 Jul;26(7):701-8 [1696575.001]
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):899-904 [8687148.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):76-86 [9887101.001]
  • [Cites] J Clin Invest. 2004 Nov;114(9):1248-59 [15520857.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10941-53 [15572695.001]
  • [Cites] J Exp Med. 2005 Jul 4;202(1):47-59 [15998787.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2605-13 [16284385.001]
  • [Cites] Mutat Res. 2005 Dec 11;591(1-2):93-102 [16054659.001]
  • [Cites] Mol Cell. 2006 Mar 3;21(5):689-700 [16507366.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] PLoS Med. 2006 Oct;3(10):e420 [17020408.001]
  • [Cites] Drug Metab Rev. 2006;38(4):769-89 [17145701.001]
  • [Cites] Neurotoxicology. 2006 Dec;27(6):1094-100 [16959318.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:89-116 [16968214.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):154-62 [17237276.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Nov 3;362(4):816-21 [17822677.001]
  • [Cites] Endocr Relat Cancer. 2009 Jun;16(2):363-80 [19190080.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Jun 15;237(3):267-80 [19303893.001]
  • [Cites] Mol Cell. 2009 Jun 26;34(6):663-73 [19560419.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Carcinogenesis. 2009 Sep;30(9):1571-80 [19608619.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Oct 1;240(1):8-14 [19538980.001]
  • [Cites] Eur J Pharmacol. 2009 Oct 12;620(1-3):138-44 [19698707.001]
  • [Cites] Free Radic Biol Med. 2009 Dec 1;47(11):1619-31 [19751820.001]
  • [Cites] J Pathol. 2010 Mar;220(4):446-51 [19967722.001]
  • [Cites] Diabetes. 2010 Apr;59(4):850-60 [20103708.001]
  • [Cites] Curr Opin Obstet Gynecol. 2008 Feb;20(1):26-33 [18197002.001]
  • [Cites] Cancer Lett. 2008 Feb 18;260(1-2):96-108 [18036733.001]
  • [Cites] Carcinogenesis. 2008 Jun;29(6):1235-43 [18413364.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7975-84 [18829555.001]
  • [Cites] Planta Med. 2008 Oct;74(13):1540-7 [18937168.001]
  • [Cites] J Obstet Gynaecol Res. 2008 Oct;34(5):776-83 [18958927.001]
  • [Cites] Pharmacol Res. 2008 Nov-Dec;58(5-6):262-70 [18838122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3410-5 [11248092.001]
  • (PMID = 20530669.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA23074; United States / NCI NIH HHS / CA / P30 CA023074; United States / NIEHS NIH HHS / ES / ES015010-04; United States / NIEHS NIH HHS / ES / R01 ES015010-04; United States / NIEHS NIH HHS / ES / ES015010; United States / NIEHS NIH HHS / ES / R01 ES015010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / KEAP1 protein, human; 0 / NF-E2-Related Factor 2; 0 / NFE2L2 protein, human; 0 / RNA, Messenger; 0 / RNA, Small Interfering; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS203767; NLM/ PMC2896449
  •  go-up   go-down


6. Marioni G, Savastano M, Mattiello L, Koussis H, Carpenè S, Marino F, Staffieri A: Tongue base metastasis from neuroendocrine endometrial small cell carcinoma. Am J Otolaryngol; 2007 Jul-Aug;28(4):284-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tongue base metastasis from neuroendocrine endometrial small cell carcinoma.
  • The endometrial small cell carcinoma (ESCC) is a rare and aggressive malignancy with an estimated prevalence of less than 1% of endometrial carcinomas.
  • Endometrial small cell carcinoma is frequently diagnosed at an advanced stage and has a poor prognosis.
  • Although the most common presenting sign of ESCC is definitely a peri- or postmenopausal vaginal bleeding, we report for the first time the occurrence of tongue base bleeding as first manifestation of disseminated neuroendocrine ESCC.
  • From a clinical viewpoint, tongue metastasis from primary endometrial carcinoma is a manifestation of widespread disease.
  • Albeit, our patient underwent complete hysterectomy and postoperative chemotherapy, she died of disseminated disease 3 months after ESCC diagnosis.
  • [MeSH-major] Carcinoma, Small Cell / secondary. Endometrial Neoplasms / pathology. Tongue Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606050.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Balendiran GK: Fibrates in the chemical action of daunorubicin. Curr Cancer Drug Targets; 2009 May;9(3):366-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anthracyclines are an important reagent in many chemotherapy regimes for treating a wide range of tumors.
  • Natural product, daunorubicin a toxic analogue of anthracycline is reduced to less toxic daunorubicinol by the AKR1B10, enzyme, which is overexpressed in most cases of smoking associate squamous cell carcinoma (SCC) and adenocarcinoma.
  • In addition, AKR1B10 was discovered as an enzyme overexpressed in human liver, cervical and endometrial cancer cases in samples from uterine cancer patients.
  • Also, the expression of AKR1B10 was associated with tumor recurrence after surgery and keratinization of squamous cell carcinoma in cervical cancer and estimated to have the potential as a tumor intervention target colorectal cancer cells (HCT-8) and diagnostic marker for non-small-cell lung cancer.
  • [MeSH-major] Clofibric Acid / therapeutic use. Daunorubicin / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Aldehyde Reductase / chemistry. Aldehyde Reductase / drug effects. Aldehyde Reductase / genetics. Aldehyde Reductase / metabolism. Antibiotics, Antineoplastic / therapeutic use. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Kinetics. Models, Molecular. Substrate Specificity

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19442055.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R15 DK085496
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 53PF01Q249 / Clofibric Acid; EC 1.1.1.- / AKR1B10 protein, human; EC 1.1.1.21 / Aldehyde Reductase; ZS7284E0ZP / Daunorubicin
  • [Number-of-references] 39
  •  go-up   go-down


8. Crowder S, Tuller E: Small cell carcinoma of the female genital tract. Semin Oncol; 2007 Feb;34(1):57-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the female genital tract.
  • Small cell carcinoma (SCC) of the female genital tract is rare, constituting less than 2% of all gynecologic malignancies.
  • Therapy has included surgery, radiation, and chemotherapy akin to those regimens used for SCC of the lung.
  • Although there are no randomized clinical trials, it appears that multimodality therapy is associated with the best results and is the treatment of choice for most patients.
  • Despite aggressive therapy, however, the prognosis for SCC of the female genital tract is poor, with only a minority of patients enjoying a prolonged survival.
  • [MeSH-major] Carcinoma, Small Cell. Genital Neoplasms, Female
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cranial Irradiation. Diagnosis, Differential. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / epidemiology. Female. Humans. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / pathology. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / therapy

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270667.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 41
  •  go-up   go-down


9. Irving JA, McFarland DF, Stuart DS, Gilks CB: Mitotic arrest of endometrial epithelium after paclitaxel therapy for breast cancer. Int J Gynecol Pathol; 2000 Oct;19(4):395-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitotic arrest of endometrial epithelium after paclitaxel therapy for breast cancer.
  • We report the histopathologic findings in endometrial curettings from a 31-year-old woman with dysfunctional uterine bleeding who had received paclitaxel therapy for breast carcinoma.
  • Paclitaxel, a member of the taxane family of antineoplastic agents that is used in the treatment of breast carcinoma, ovarian carcinoma, and non-small cell lung carcinoma, acts by the simultaneous promotion of tubulin assembly into microtubules and inhibition of microtubule disassembly.
  • Cell divisions were arrested in metaphase.
  • [MeSH-major] Breast Neoplasms / drug therapy. Endometrium / pathology. Mitosis. Paclitaxel / administration & dosage. Uterine Hemorrhage / chemically induced
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Antigens, Nuclear. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Dilatation and Curettage. Doxorubicin / administration & dosage. Epithelium / chemistry. Epithelium / pathology. Female. Humans. Ki-67 Antigen. Menorrhagia / surgery. Nuclear Proteins / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Tissue Embedding

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Bleeding.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11109173.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Deppe G, Baumann P: [Treatment strategies for endometrial cancer]. Zentralbl Gynakol; 2004 Oct;126(5):306-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment strategies for endometrial cancer].
  • This paper focuses on the controversies surrounding management of endometrial cancer, the most common carcinoma of the female genital tract.
  • Actual treatment suggestions are attached as tables.
  • Adenocarcinomas represent the majority of endometrial cancers.
  • In contrast, papillary-serous and clear cell carcinomas comprise 1-10 % of endometrial cancers.
  • While adenocarcinomas may well be treated by surgery and radiation therapy, identifying appropriate treatment modalities for patients with papillary-serous and clear cell carcinoma and poor prognosis is of critical importance.
  • Data on radiation therapy or chemotherapy, to date, are of limited value secondary to small sample sizes and the heterogeneous treatment modalities that many times were applied.
  • Individualized treatment strategies have to take into account accompanying co-morbidities, more importantly, though, whether the patient underwent surgical staging.
  • [MeSH-major] Endometrial Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Trials as Topic. Female. Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15478048.001).
  • [ISSN] 0044-4197
  • [Journal-full-title] Zentralblatt für Gynäkologie
  • [ISO-abbreviation] Zentralbl Gynakol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 33
  •  go-up   go-down


11. Toyoda H, Hirai T, Ishii E: Alpha-fetoprotein producing uterine corpus carcinoma: A hepatoid adenocarcinoma of the endometrium. Pathol Int; 2000 Oct;50(10):847-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein producing uterine corpus carcinoma: A hepatoid adenocarcinoma of the endometrium.
  • A case of alpha-fetoprotein (AFP) producing endometrial carcinoma in a 60-year-old Japanese woman is presented.
  • Histologically, the biopsy specimen taken from the uterine mass showed a poorly differentiated endometrial carcinoma and a radical hysterectomy was subsequently performed.
  • The postoperative serum AFP value transiently decreased with chemotherapy, however, lung metastases were found and the patient died 12 months following surgery.
  • The resected uterus had a necrotic tumor, 6 x 5 x 4 cm in size, filling the endometrial cavity, characterized by exophytic growth with infiltration in the myometrium.
  • Histologically, the tumor was composed of the main medullary carcinoma area with microcysts and admixed small areas of well-differentiated endometrioid adenocarcinoma, accompanied by a smooth transition with one another.
  • There was no histologic evidence for a germ cell tumor.
  • Based on these findings, this uterine corpus tumor was regarded as hepatoid variant of endometrial carcinoma.
  • Although the histogenesis remains controversial, we assume the hypothesis that the tumor may arise in the endometrium per se in association with abnormal differentiation of muellerian duct elements.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11107058.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins
  •  go-up   go-down


12. Terada T: KIT-positive primary small cell carcinoma of the endometrium: a case report with immunohistochemical and molecular genetic analysis of KIT and PDGFRA genes. Arch Gynecol Obstet; 2010 Oct;282(4):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT-positive primary small cell carcinoma of the endometrium: a case report with immunohistochemical and molecular genetic analysis of KIT and PDGFRA genes.
  • BACKGROUND: Primary small cell carcinoma of the endometrium is very rare, and there have been no reports on KIT and PDGFRA in endometrial small cell carcinoma.
  • Endometrial cytology and biopsy revealed small cell carcinoma.
  • Scrutiny of the body showed stage III endometrial carcinoma with metastases.
  • The patient received chemotherapy and radiation, but showed a downhill course, and died of carcinomatosis 6 months after the initial presentation.
  • CONCLUSION: The present case is the first reported case of primary small cell carcinoma of the endometrium with an examination of KIT and PDGFRA expressions and KIT and PDFGRA gene mutations.
  • [MeSH-major] Carcinoma, Small Cell / genetics. Endometrial Neoplasms / genetics. Proto-Oncogene Proteins c-kit / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics
  • [MeSH-minor] Aged, 80 and over. Biopsy. DNA Mutational Analysis. Drug Therapy. Fatal Outcome. Female. Humans. Immunohistochemistry. Polymerase Chain Reaction. Radiotherapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20035340.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


13. Varras M, Akrivis Ch, Demou A, Hadjopoulos G, Stefanaki S, Antoniou N: Primary small-cell carcinoma of the endometrium: clinicopathological study of a case and review of the literature. Eur J Gynaecol Oncol; 2002;23(6):577-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small-cell carcinoma of the endometrium: clinicopathological study of a case and review of the literature.
  • BACKGROUND: Small-cell carcinomas are almost always primary in the lungs and are highly malignant.
  • However, primary small-cell carcinoma of the endometrium is extremely rare with very few cases reported in the English literature.
  • CASE: A 55-year-old postmenopausal woman with primary small-cell carcinoma of the endometrium, FIGO stage Ib, underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and sampling node biopsies of the parametrial spaces, followed by adjuvant combined chemotherapy.
  • CONCLUSION: A case of small-cell carcinoma of the endometrium, is reported and its clinical, histological and immunohistochemical features are discussed.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Endometrial Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12556112.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 26
  •  go-up   go-down


14. Yuan R, Kay A, Berg WJ, Lebwohl D: Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol; 2009 Oct 27;2:45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.
  • Consequently, inhibitors of mTOR, including temsirolimus, everolimus, and ridaforolimus (formerly deforolimus) have been developed and assessed for their safety and efficacy in patients with cancer.
  • Temsirolimus is an intravenously administered agent approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of advanced renal cell carcinoma (RCC).
  • Everolimus is an oral agent that has recently obtained US FDA and EMEA approval for the treatment of advanced RCC after failure of treatment with sunitinib or sorafenib.
  • The use of mTOR inhibitors, either alone or in combination with other anticancer agents, has the potential to provide anticancer activity in numerous tumor types.
  • Cancer types in which these agents are under evaluation include neuroendocrine tumors, breast cancer, leukemia, lymphoma, hepatocellular carcinoma, gastric cancer, pancreatic cancer, sarcoma, endometrial cancer, and non-small-cell lung cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cell Transformation, Neoplastic / drug effects. Drug Delivery Systems / methods. Drug Discovery. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Neoplasms / drug therapy. Protein-Serine-Threonine Kinases / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1588-95 [18332470.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2756-62 [18451242.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1596-602 [18332467.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3063-72 [18565894.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):508-14 [18543327.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4311-8 [18779618.001]
  • [Cites] BJU Int. 2009 Mar;103(5):572-7 [19154471.001]
  • [Cites] Eur J Cancer. 2009 Mar;45(5):765-73 [19157861.001]
  • [Cites] Cancer. 2009 Jun 1;115(11):2438-46 [19306412.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2630-7 [19380449.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3822-9 [19581539.001]
  • [Cites] Ann Oncol. 2009 Oct;20(10):1674-81 [19549709.001]
  • [Cites] J Clin Oncol. 2010 Jan 1;28(1):69-76 [19933912.001]
  • [Cites] J Clin Oncol. 2010 Apr 10;28(11):1904-10 [20231677.001]
  • [Cites] Cancer. 2010 Dec 1;116(23):5415-9 [20681032.001]
  • [Cites] J Biol Chem. 1999 Nov 12;274(46):33085-91 [10551878.001]
  • [Cites] Gut. 2000 Aug;47(2):272-6 [10896921.001]
  • [Cites] Breast Cancer Res. 2000;2(5):335-44 [11250726.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):289-96 [11773181.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3659-62 [12097271.001]
  • [Cites] Microbiol Mol Biol Rev. 2002 Dec;66(4):579-91, table of contents [12456783.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):420-4 [12853790.001]
  • [Cites] N Engl J Med. 2003 Aug 28;349(9):847-58 [12944570.001]
  • [Cites] Trends Biochem Sci. 2003 Nov;28(11):573-6 [14607085.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5078-84 [14613984.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7652-6 [14633685.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):909-18 [14990647.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):335-48 [15122205.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2336-47 [15136596.001]
  • [Cites] Nature. 2006 May 25;441(7092):424-30 [16724053.001]
  • [Cites] Expert Opin Emerg Drugs. 2007 Nov;12(4):605-18 [17979602.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(1):84-91 [18039566.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):361-7 [18202410.001]
  • [Cites] Mod Pathol. 2008 Mar;21(3):231-7 [18157089.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1576-8 [18332465.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1603-10 [18332469.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2954-63 [15254063.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):91-9 [15261145.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1510-6 [15367412.001]
  • [Cites] J Antibiot (Tokyo). 1975 Oct;28(10):727-32 [1102509.001]
  • [Cites] Cancer Treat Rev. 1981 Mar;8(1):63-87 [7248995.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3581-7 [10446965.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122(6):931-7 [15539386.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4991-5004 [15611513.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2047-53 [15781610.001]
  • [Cites] Biochim Biophys Acta. 2005 Nov 25;1756(2):127-44 [16139957.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2028-37 [16489002.001]
  • [Cites] Nephrol Dial Transplant. 2006 Jul;21 Suppl 3:iii18-23 [16815852.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):671-88 [16883305.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5755-63 [17020981.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1148-54 [17031397.001]
  • [Cites] Kidney Int. 2006 Nov;70(10):1777-82 [17003820.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7215-20 [17189392.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S15-24 [17259554.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):163-72 [17382271.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):599-605 [17577220.001]
  • [Cites] Pathology. 2007 Oct;39(5):482-5 [17886097.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Nov;64(2):115-28 [17702596.001]
  • (PMID = 19860903.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Intracellular Signaling Peptides and Proteins; 0 / Protein Kinase Inhibitors; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Number-of-references] 103
  • [Other-IDs] NLM/ PMC2775749
  •  go-up   go-down


15. Ju W, Park IA, Kim SH, Lee SE, Kim SC: Small cell carcinoma of the uterine corpus manifesting with visual dysfunction. Gynecol Oncol; 2005 Nov;99(2):504-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the uterine corpus manifesting with visual dysfunction.
  • BACKGROUND: Small cell carcinoma in the uterine corpus rather than the endometrium has not been reported yet which resembles a uterine leiomyosarcoma on an imaging study.
  • This uterine mass mimicking a leiomyosarcoma on pelvis MRI was identified to be a small cell carcinoma via a transvaginal gun biopsy and consequent immunostaining.
  • The patient was then scheduled to undergo a regimen of chemotherapy with etoposide and carboplatin.
  • CONCLUSION: Small cell carcinoma may arise from the uterine corpus rather than the endometrium and may also be accompanied by visual symptoms.
  • [MeSH-major] Carcinoma, Small Cell / complications. Uterine Neoplasms / complications. Vision Disorders / etiology
  • [MeSH-minor] Diagnosis, Differential. Endometrial Neoplasms / diagnosis. Female. Humans. Leiomyosarcoma / diagnosis. Middle Aged. Paraneoplastic Syndromes / etiology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112716.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Posligua L, Malpica A, Liu J, Brown J, Deavers MT: Combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium with pagetoid spread. Arch Pathol Lab Med; 2008 Nov;132(11):1821-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium with pagetoid spread.
  • Recently, a case of combined small cell carcinoma and papillary serous carcinoma of the endometrium was described for the first time.
  • We report the first case, to our knowledge, of combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium, with an unusual pagetoid spread of the neuroendocrine component into normal endometrial and endocervical glands.
  • The endometrial carcinoma had a small serous component, but most of the tumor was characterized by solid sheets of medium to large cells with abundant mitotic figures, numerous apoptotic bodies, and foci of necrosis.
  • Following surgery, the patient was treated with radiation therapy and chemotherapy.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Papillary / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] Cell Differentiation. Combined Modality Therapy. Female. Humans. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976022.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / R01 CA131183
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Yang YJ, Trapkin LK, Demoski RK, Bellerdine J, Powers CN: The small blue cell dilemma associated with tamoxifen therapy. Arch Pathol Lab Med; 2001 Aug;125(8):1047-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The small blue cell dilemma associated with tamoxifen therapy.
  • CONTEXT: Several endometrial diseases, such as endometrial hyperplasia, endometrial carcinoma, and endometrial polyps, have been reported to be associated with tamoxifen administration.
  • We recently observed a high incidence of distinctive small blue cells in Papanicolaou tests of women who had received tamoxifen treatment for breast carcinoma.
  • OBJECTIVES: To define the characteristics of these small blue cells, to identify the patient population in which they are found, and to determine the clinical significance and possible etiology of these findings.
  • DESIGN: A total of 154 Papanicolaou tests from 60 patients with a clinical history of tamoxifen therapy were reviewed retrospectively.
  • RESULTS: Small blue cells were found in 40% of Papanicolaou tests from patients who received tamoxifen therapy.
  • Patients with small blue cells in their Papanicolaou tests were an average of 9 years older at the time tamoxifen therapy was initiated than those without.
  • CONCLUSIONS: We conclude that these distinctive small blue cells are found more frequently in older patients and most probably represent proliferative reserve cells of cervical/vaginal epithelium resulting from the estrogenic agonist effect of tamoxifen.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Atrophy. Breast Neoplasms / drug therapy. Endometrial Neoplasms / chemically induced. Endometrium / pathology. Epithelium / pathology. Female. Humans. Hysterectomy. Menstrual Cycle. Middle Aged


18. Schally AV, Nagy A: Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab; 2004 Sep;15(7):300-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy targeted to cancers through tumoral hormone receptors.
  • Work on cytotoxic analogs of luteinizing hormone-releasing hormone (LH-RH), somatostatin and bombesin, designed for targeting chemotherapy to peptide receptors on various cancers, is reviewed here as the project is at advanced stages of development and clinical trials are pending.
  • Cytotoxic analogs of LH-RH, AN-152 and AN-207, containing doxorubicin (DOX) or 2-pyrrolino-DOX (AN-201), respectively, target LH-RH receptors and can be used for the treatment of prostatic, breast, ovarian and endometrial cancers and melanomas.
  • A cytotoxic analog of bombesin AN-215, containing 2-pyrrolino-DOX, was likewise synthesized and successfully tested in experimental models of prostate cancer, small cell lung carcinoma, gastrointestinal cancers and brain tumors expressing receptors for bombesin/gastrin-releasing peptide.
  • This new class of targeted cytotoxic peptide analogs might provide a more effective therapy for various cancers.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Drug Delivery Systems. Neoplasms / drug therapy. Neoplasms / metabolism. Receptors, Cell Surface / drug effects
  • [MeSH-minor] Animals. Bombesin / analogs & derivatives. Bombesin / therapeutic use. Gastrin-Releasing Peptide / analogs & derivatives. Gastrin-Releasing Peptide / therapeutic use. Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropin-Releasing Hormone / therapeutic use. Humans. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use


19. Koukourakis MI, Giatromanolaki A, Sivridis E, Fezoulidis I: Cancer vascularization: implications in radiotherapy? Int J Radiat Oncol Biol Phys; 2000 Sep 1;48(2):545-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The distribution of the vascular density within tumors was studied in 436 non-small-cell lung carcinomas and 298 breast carcinomas.
  • (1) tumors with low or (2) tumors with high vessel density throughout the tissue section, and (3) tumors with high vessel density in the tumor periphery and low in inner areas.
  • The death rate following surgery showed a direct association with the vascular density in lung, breast, colon, and endometrial cancer.
  • In inoperable gastric cancer patients treated with chemotherapy, and in head and neck cancer patients treated with radical chemoradiotherapy there was a 'U-like' association of the death rate with the vascular density suggesting that very low (poor oxygen and drug availability) and very high (intensified angiogenic pathways) vascularization are both linked to poor outcome.
  • CONCLUSION: The present study stresses the importance of the vascular density as a putative variable that may have affected the results of large clinical trials that investigated the role of anemia, hyperbaric oxygen, hypoxic sensitizers, or even of combined chemoradiotherapy in the outcome of radiation treatment.
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / radiotherapy. Breast Neoplasms / blood supply. Breast Neoplasms / radiotherapy. Carcinoma, Non-Small-Cell Lung / blood supply. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / radiotherapy. Colonic Neoplasms / blood supply. Colonic Neoplasms / radiotherapy. Endometrial Neoplasms / blood supply. Endometrial Neoplasms / radiotherapy. Female. Humans. Lung Neoplasms / blood supply. Lung Neoplasms / radiotherapy. Microcirculation. Oxygen Consumption. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10974475.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


20. Omuro AM, Raizer JJ, Demopoulos A, Malkin MG, Abrey LE: Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. J Neurooncol; 2006 Jul;78(3):277-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Temozolomide (TMZ) has shown modest efficacy in the treatment of recurrent brain metastasis (BM).
  • Chemotherapy consisted of 28-day cycles with TMZ (150 mg/m2, days 1-7 and 15-21) and vinorelbine (days one and eight at escalating doses).
  • The primary tumor was lung cancer in 13 patients (NSCLC in 10, SCLC in 3), breast in 6, renal in 1 and endometrial in 1.
  • Grades 3 and 4 neutropenia developed in six patients, lymphopenia in nine, and thrombocytopenia in six; other toxicities were rare.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lymphopenia / chemically induced. Male. Maximum Tolerated Dose. Middle Aged. Neutropenia / chemically induced. Thrombocytopenia / chemically induced. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Mar 3;352(9):895-904 [15745980.001]
  • [Cites] Br J Cancer. 2000 Jun;82(12):1907-13 [10864196.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1004-11 [12671695.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):249-54 [11300333.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17 ):3644-50 [12202665.001]
  • [Cites] Neurology. 2004 Sep 14;63(5):901-3 [15365145.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] N Engl J Med. 2005 Mar 3;352(9):930-2 [15745986.001]
  • [Cites] Neurology. 2004 Jun 8;62(11):2113-5 [15184628.001]
  • [Cites] Cancer Invest. 2002;20(3):293-302 [12025223.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):259-65 [11718258.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):147-52 [12764672.001]
  • [Cites] Lung Cancer. 1999 Oct;26(1):35-9 [10574679.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):420-5 [11786569.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1271-6 [12763216.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):59-67 [11249050.001]
  • [Cites] Oncology. 2003;64(1):28-35 [12457029.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2114-20 [14522368.001]
  • [Cites] Am J Clin Oncol. 1997 Jun;20(3):303-7 [9167759.001]
  • [Cites] Anticancer Drugs. 1996 Feb;7(2):213-9 [8740728.001]
  • [Cites] Curr Neurol Neurosci Rep. 2004 May;4(3):205-10 [15102346.001]
  • [Cites] Arzneimittelforschung. 1993 Dec;43(12):1367-77 [8141830.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):185-91 [15629610.001]
  • (PMID = 16614943.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; Q6C979R91Y / vinorelbine; YF1K15M17Y / temozolomide
  •  go-up   go-down


21. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, Malkin MG: A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol; 2001 Jul;53(3):259-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Treatment options for patients with recurrent brain metastases are extremely limited.
  • This study was designed to determine the safety and efficacy of temozolomide in the treatment of recurrent or progressive brain metastases.
  • PATIENTS AND METHODS: Forty-one patients (11 men, 30 women) with a median KPS of 80 were treated with temozolomide 150 mg/m2/day (200 mg/m3/day if no prior chemotherapy) for 5 days; treatment cycles were repeated every 28 days.
  • Primary tumor types included 22 non-small cell lung, 10 breast, three melanoma, two small cell lung, two rectal, one ovarian and one endometrial cancer.
  • Both objective responses were seen in patients with non-small cell lung cancer.
  • Therefore, temozolomide may be a reasonable treatment option for some patients with recurrent brain metastases.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / therapeutic use
  • [MeSH-minor] Adult. Aged. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / secondary. Disease Progression. Female. Humans. Lung Neoplasms. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):229-38 [1374064.001]
  • [Cites] Am J Clin Oncol. 1997 Apr;20(2):158-60 [9124191.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):249-54 [11300333.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):765-73 [8625178.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):517-26 [8823779.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1063-70 [9060546.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):600-4 [7674007.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 4;87(1):34-40 [7666461.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1599-605 [10193952.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):527-36 [8823780.001]
  • [Cites] Br J Neurosurg. 1994;8(6):717-23 [7718169.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10 ):1769-74 [9815562.001]
  • (PMID = 11718258.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


22. Boran N, Akdag D, Halici F, Tulunay G, Turan T, Bozok S, Erdogan Z, Kose MF: A retrospective analysis of the diameter of metastatic lymph nodes in apparently early stage endometrial cancer. Tumori; 2008 Sep-Oct;94(5):681-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective analysis of the diameter of metastatic lymph nodes in apparently early stage endometrial cancer.
  • AIMS AND BACKGROUND: The objective of this retrospective study was to assess the diameter of metastatic lymph nodes in a population of women with apparently early stage endometrial cancer at laparotomy.
  • METHODS AND STUDY DESIGN: Among 700 cases with endometrial cancer, 27 cases with disease clinically limited to the uterus in the laparotomy and found to have retroperitoneal node metastasis after pathologic examination were included in this study.
  • CONCLUSIONS: The diameters of metastatic nodes may be as small as 1 mm.
  • By sampling or selective para-aortic and/or pelvic lymphadenectomy, some of the nodes might go undiagnosed, and such understaged cases cannot take adjuvant therapy (chemotherapy-radiotherapy).
  • For correct staging of cases with endometrial cancer, complete systematic para-aortic and/or pelvic lymphadenectomy might be appropriate.
  • [MeSH-major] Endometrial Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adult. Aged. Aorta. Carcinoma, Endometrioid / secondary. Carcinosarcoma / secondary. Cystadenocarcinoma, Serous / secondary. Female. Humans. Hysterectomy. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovariectomy. Pelvis. Retrospective Studies

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112940.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Korcum AF, Aksu G, Ozdogan M, Erdogan G, Taskin O: Stage I small cell carcinoma of the endometrium: survival and management options. Acta Obstet Gynecol Scand; 2008;87(1):122-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I small cell carcinoma of the endometrium: survival and management options.
  • Small cell carcinoma (SCC) of the endometrium is a rare but aggressive disease with early systemic involvement.
  • To date, no effective treatment protocol has been established.
  • Surgery, radiotherapy, and chemotherapy have been used either alone or in combination.
  • The case of a patient with stage IB endometrial SCC is presented with an overview based on all reported cases of SCC of the endometrium and its treatment with particular reference to stage I cases.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Endometrial Neoplasms / therapy
  • [MeSH-minor] Brachytherapy. Combined Modality Therapy. Drug Therapy. Female. Humans. Hysterectomy. Middle Aged

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943466.001).
  • [ISSN] 1600-0412
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


24. Subramaniam R, Arnott SJ, Leslie MD: Successful chemoradiotherapy for anal cancer despite previous radical radiotherapy for gynaecological malignancy. Clin Oncol (R Coll Radiol); 2002 Aug;14(4):285-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Repeat radical irradiation of the pelvis is generally not undertaken because of concerns regarding normal tissue damage; in particular to small bowel, bladder and bone.
  • Two patients with carcinoma of the anal canal are presented who had previously been treated by radical pelvic radiotherapy for gynaecological malignancy.
  • Both were re-treated with radical radiotherapy to the pelvis with concomitant chemotherapy.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Female. Fluorouracil / therapeutic use. Humans. Hysterectomy. Mitomycin / therapeutic use. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12206638.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Heinemann V, Moosmann N: [Neoadjuvant and adjuvant therapies for solid tumours]. MMW Fortschr Med; 2007 Sep 6;149(35-36):27-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant and adjuvant therapies for solid tumours].
  • Today adjuvant or neoadjuvant therapies are standard treatment for many types of cancer.
  • Chemotherapy, radiotherapy, hormone therapy or immunotherapy applied before, during or after an operation can lower the risk of relapse and hence, increase the chances of a cure.
  • After neoadjuvant therapy, frequently the organ does not have to be removed in the subsequent operation.
  • Depending on the risk of relapse, adjuvant therapies are employed after due consideration of benefit, risk and duration of treatment.
  • [MeSH-major] Chemotherapy, Adjuvant. Neoadjuvant Therapy. Neoplasms / therapy. Radiotherapy, Adjuvant
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Non-Small-Cell Lung / surgery. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Esophageal Neoplasms / surgery. Female. Humans. Informed Consent. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy. Lung Neoplasms / surgery. Male. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery. Prognosis. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery. Rectal Neoplasms / drug therapy. Rectal Neoplasms / pathology. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / surgery. Risk Factors. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17944281.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 0
  •  go-up   go-down


26. Murphy KT, Rotmensch J, Yamada SD, Mundt AJ: Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys; 2003 Apr 1;55(5):1272-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
  • PURPOSE: To evaluate the outcome and patterns of failure in women with uterine clear-cell carcinoma and discuss implications for adjuvant radiation therapy (RT).
  • METHODS: Between 1980 and 2000, 686 endometrial carcinoma patients underwent primary surgery at our institution.
  • Thirty-eight women (5.5%) had clear-cell tumors (18 clear-cell only, 8 clear-cell + adenocarcinoma, and 12 clear-cell + other unfavorable histologies [10 papillary serous, 1 uterine sarcoma, 1 both]).
  • Adjuvant therapies included the following: 5 none, 22 RT (13 pelvic RT, 2 vaginal brachytherapy, 7 both), 11 chemotherapy (8 alone, 3 after pelvic RT), and 3 hormones.
  • Patients with clear +/- adenocarcinoma histology had a similar 5-year disease-free survival (38.8% vs. 38.7%, p = 0.95) compared with those with clear-cell + other unfavorable histologies.
  • Only 1 (2%) patient developed an isolated abdominal failure (This patient had a mixed clear-cell/papillary serous tumor).
  • Of the 26 women with clear-cell +/- adenocarcinoma histology, only 1 (3.8%) relapsed in the abdomen.
  • CONCLUSION: Clear-cell carcinoma comprises a small percentage of endometrial cancers, frequently presents as a mixed histology, and has a poor overall outcome.
  • Unlike papillary serous tumors, clear-cell carcinoma does not seem to have a high propensity for abdominal failure.
  • Future protocols should focus instead on combinations of locoregional RT and chemotherapy to reduce the risk of local and systemic recurrence.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometrial Neoplasms / pathology. Radiotherapy, Adjuvant
  • [MeSH-minor] Abdominal Neoplasms / secondary. Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Brachytherapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cystadenocarcinoma / pathology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy. Life Tables. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / mortality. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Pelvic Neoplasms / secondary. Prognosis. Sarcoma / pathology. Treatment Failure. Treatment Outcome. Uterine Neoplasms / pathology. Vaginal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12654437.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 30
  •  go-up   go-down


27. Albores-Saavedra J, Martinez-Benitez B, Luevano E: Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: polypoid tumors and those arising in polyps may have a favorable prognosis. Int J Gynecol Pathol; 2008 Jul;27(3):333-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: polypoid tumors and those arising in polyps may have a favorable prognosis.
  • We report 5 polypoid high-grade neuroendocrine carcinomas of the uterus, 2 small cell carcinomas of the endometrium, and 3 large cell neuroendocrine carcinomas, 2 from the cervix and 1 from the endometrium.
  • The 2 small cell carcinomas of the endometrium arose from and were confined to endometrial polyps, one of which also showed foci of endometrioid adenocarcinoma.
  • The 3 large cell neuroendocrine carcinomas, 2 from the cervix and 1 from the endometrium, were polypoid but did not originate in polyps.
  • All 5 patients were treated by radical hysterectomy and 4 received adjuvant chemotherapy.
  • All patients are alive and disease-free from 9 months to 7 years after treatment (mean survival, 47 months).
  • Two small cell carcinomas and 2 large cell neuroendocrine carcinomas accumulated p53 protein.
  • Two small cell carcinomas and 2 large cell neuroendocrine carcinomas expressed p16.
  • Our findings suggest that stage of disease and a polypoid gross feature are the best predictors for outcome in small cell carcinomas and large cell neuroendocrine carcinomas of the uterus.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Endometrial Neoplasms / pathology. Neuroendocrine Tumors / pathology. Polyps / pathology. Uterine Cervical Neoplasms / pathology






Advertisement